CTLA-4单抗-话题@MedSci

#CTLA-4单抗#

9篇内容 | 708人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2182923, encodeId=001521829238b, content=<a href='/topic/show?id=493ae869206' target=_blank style='color:#2F92EE;'>#结直肠癌#</a> <a href='/topic/show?id=34b54848271' target=_blank style='color:#2F92EE;'>#帕博利珠单抗#</a> <a href='/topic/show?id=fe305409c3' target=_blank style='color:#2F92EE;'>#CTLA-4单抗#</a> <a href='/topic/show?id=b3b31103229a' target=_blank style='color:#2F92EE;'>#muzastotug#</a> <a href='/topic/show?id=732511032388' target=_blank style='color:#2F92EE;'>#ADG126#</a>, objectTitle=新型CTLA-4单抗ADG126联合PD-1帕博利珠单抗治疗结直肠癌，效果卓著, objectType=article, longId=810252, objectId=f8ab81025229, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20240118/9c46d1987465406fb9bc4bf507cf4d0c.jpg, objectUrl=/article/show_article.do?id=f8ab81025229, replyNumber=0, likeNumber=32, createdTime=2024-01-21, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=加利福尼亚, moduleDTOList=[ModuleDTO(moduleId=f8ab81025229, moduleTitle=新型CTLA-4单抗ADG126联合PD-1帕博利珠单抗治疗结直肠癌，效果卓著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f8ab81025229)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1777351, encodeId=ca001e77351e0, content=<a href='/topic/show?id=fe305409c3' target=_blank style='color:#2F92EE;'>#CTLA-4单抗#</a>, objectTitle=百奥赛图与TRACON共同宣布YH001（CTLA-4单抗）联合恩沃利单抗（PD-L1）一线治疗软组织肉瘤的临床试验申请获得FDA批准, objectType=article, longId=737420, objectId=555de3742013, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=555de3742013, replyNumber=0, likeNumber=61, createdTime=2023-06-30, rootId=0, userName=shalley79, userId=875639161194, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=555de3742013, moduleTitle=百奥赛图与TRACON共同宣布YH001（CTLA-4单抗）联合恩沃利单抗（PD-L1）一线治疗软组织肉瘤的临床试验申请获得FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=555de3742013)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777350, encodeId=49801e7735043, content=<a href='/topic/show?id=fe305409c3' target=_blank style='color:#2F92EE;'>#CTLA-4单抗#</a>, objectTitle=FDA批准百时美施贵宝的PD-1单抗Opdivo和CTLA-4单抗Yervoy组合，一线治疗非小细胞肺癌, objectType=article, longId=221346, objectId=ab662213469b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab662213469b, replyNumber=0, likeNumber=43, createdTime=2022-03-24, rootId=0, userName=shalley79, userId=875639161194, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab662213469b, moduleTitle=FDA批准百时美施贵宝的PD-1单抗Opdivo和CTLA-4单抗Yervoy组合，一线治疗非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab662213469b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777348, encodeId=138b1e7734833, content=<a href='/topic/show?id=fe305409c3' target=_blank style='color:#2F92EE;'>#CTLA-4单抗#</a>, objectTitle=ASCO 2020：PD-1单抗Opdivo、CTLA-4单抗Yervoy联合化疗一线治疗非小细胞肺癌，将死亡风险降低31％, objectType=article, longId=194237, objectId=1da819423ef7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1da819423ef7, replyNumber=0, likeNumber=34, createdTime=2021-04-04, rootId=0, userName=shalley79, userId=875639161194, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1da819423ef7, moduleTitle=ASCO 2020：PD-1单抗Opdivo、CTLA-4单抗Yervoy联合化疗一线治疗非小细胞肺癌，将死亡风险降低31％, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1da819423ef7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777349, encodeId=a5891e77349f8, content=<a href='/topic/show?id=fe305409c3' target=_blank style='color:#2F92EE;'>#CTLA-4单抗#</a>, objectTitle=FDA批准百时美施贵宝的PD-1单抗Opdivo和CTLA-4单抗Yervoy组合，一线治疗非小细胞肺癌, objectType=article, longId=194250, objectId=8f001942503c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f001942503c, replyNumber=0, likeNumber=29, createdTime=2020-05-27, rootId=0, userName=shalley79, userId=875639161194, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f001942503c, moduleTitle=FDA批准百时美施贵宝的PD-1单抗Opdivo和CTLA-4单抗Yervoy组合，一线治疗非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f001942503c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777346, encodeId=e21f1e773466e, content=<a href='/topic/show?id=fe305409c3' target=_blank style='color:#2F92EE;'>#CTLA-4单抗#</a>, objectTitle=PD-1单抗Opdivo联合CTLA-4单抗Yervoy治疗肝细胞癌，获得FDA的加速批准, objectType=article, longId=189902, objectId=b3c0189902f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b3c0189902f2, replyNumber=0, likeNumber=33, createdTime=2020-10-11, rootId=0, userName=shalley79, userId=875639161194, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b3c0189902f2, moduleTitle=PD-1单抗Opdivo联合CTLA-4单抗Yervoy治疗肝细胞癌，获得FDA的加速批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b3c0189902f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777347, encodeId=12bc1e77347c2, content=<a href='/topic/show?id=fe305409c3' target=_blank style='color:#2F92EE;'>#CTLA-4单抗#</a>, objectTitle=Agenus的PD-1单抗Balstilimab联合CTLA-4单抗Zalifrelimab治疗晚期宫颈癌，获得FDA的快速通道指定, objectType=article, longId=190021, objectId=dadc19002166, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dadc19002166, replyNumber=0, likeNumber=38, createdTime=2020-07-28, rootId=0, userName=shalley79, userId=875639161194, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dadc19002166, moduleTitle=Agenus的PD-1单抗Balstilimab联合CTLA-4单抗Zalifrelimab治疗晚期宫颈癌，获得FDA的快速通道指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dadc19002166)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777345, encodeId=50b81e77345d2, content=<a href='/topic/show?id=fe305409c3' target=_blank style='color:#2F92EE;'>#CTLA-4单抗#</a>, objectTitle=FDA将对PD-1单抗Opdivo联合CTLA-4单抗Yervoy用作非小细胞肺癌的一线治疗，展开优先审查, objectType=article, longId=186455, objectId=16dd186455e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=16dd186455e4, replyNumber=0, likeNumber=49, createdTime=2020-11-29, rootId=0, userName=shalley79, userId=875639161194, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=16dd186455e4, moduleTitle=FDA将对PD-1单抗Opdivo联合CTLA-4单抗Yervoy用作非小细胞肺癌的一线治疗，展开优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=16dd186455e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777344, encodeId=f2f91e773441f, content=<a href='/topic/show?id=fe305409c3' target=_blank style='color:#2F92EE;'>#CTLA-4单抗#</a>, objectTitle=BMS的PD-1单抗Opdivo联合CTLA-4单抗Yervoy治疗非小细胞肺癌中III期临床成功, objectType=article, longId=181829, objectId=2a12181829fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a12181829fb, replyNumber=0, likeNumber=44, createdTime=2019-12-22, rootId=0, userName=shalley79, userId=875639161194, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a12181829fb, moduleTitle=BMS的PD-1单抗Opdivo联合CTLA-4单抗Yervoy治疗非小细胞肺癌中III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a12181829fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777343, encodeId=aba81e773438d, content=<a href='/topic/show?id=fe305409c3' target=_blank style='color:#2F92EE;'>#CTLA-4单抗#</a>, objectTitle=BMS的PD-1单抗联合CTLA-4单抗治疗肝细胞癌的早期临床结果很有前景, objectType=article, longId=167676, objectId=769c16e676a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=769c16e676a7, replyNumber=0, likeNumber=42, createdTime=2020-02-07, rootId=0, userName=shalley79, userId=875639161194, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=769c16e676a7, moduleTitle=BMS的PD-1单抗联合CTLA-4单抗治疗肝细胞癌的早期临床结果很有前景, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=769c16e676a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

CTLA-4单抗

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#结直肠癌# #帕博利珠单抗# #CTLA-4单抗# #muzastotug# #ADG126#

新型CTLA-4单抗ADG126联合PD-1帕博利珠单抗治疗结直肠癌，效果卓著

2024-01-21发表于加利福尼亚

shalley79 (审核中...)

前往app查看评论内容

#CTLA-4单抗#

百奥赛图与TRACON共同宣布YH001（CTLA-4单抗）联合恩沃利单抗（PD-L1）一线治疗软组织肉瘤的临床试验申请获得FDA批准

2023-06-30

shalley79 (审核中...)

前往app查看评论内容

#CTLA-4单抗#

FDA批准百时美施贵宝的PD-1单抗Opdivo和CTLA-4单抗Yervoy组合，一线治疗非小细胞肺癌

2022-03-24

shalley79 (审核中...)

前往app查看评论内容

#CTLA-4单抗#

ASCO 2020：PD-1单抗Opdivo、CTLA-4单抗Yervoy联合化疗一线治疗非小细胞肺癌，将死亡风险降低31％

2021-04-04

shalley79 (审核中...)

前往app查看评论内容

#CTLA-4单抗#

FDA批准百时美施贵宝的PD-1单抗Opdivo和CTLA-4单抗Yervoy组合，一线治疗非小细胞肺癌

2020-05-27

shalley79 (审核中...)

前往app查看评论内容

#CTLA-4单抗#

PD-1单抗Opdivo联合CTLA-4单抗Yervoy治疗肝细胞癌，获得FDA的加速批准

2020-10-11

shalley79 (审核中...)

前往app查看评论内容

#CTLA-4单抗#

Agenus的PD-1单抗Balstilimab联合CTLA-4单抗Zalifrelimab治疗晚期宫颈癌，获得FDA的快速通道指定

2020-07-28

shalley79 (审核中...)

前往app查看评论内容

#CTLA-4单抗#

FDA将对PD-1单抗Opdivo联合CTLA-4单抗Yervoy用作非小细胞肺癌的一线治疗，展开优先审查

2020-11-29

shalley79 (审核中...)

前往app查看评论内容

#CTLA-4单抗#

BMS的PD-1单抗Opdivo联合CTLA-4单抗Yervoy治疗非小细胞肺癌中III期临床成功

2019-12-22

shalley79 (审核中...)

前往app查看评论内容

#CTLA-4单抗#

BMS的PD-1单抗联合CTLA-4单抗治疗肝细胞癌的早期临床结果很有前景

2020-02-07

科室
- - 订阅+
  - 更多科室
工具
服务